We are conducting research and development with the goal of developing a small molecule brain tumor treatment that simultaneously targets new brain tumor targets with our main pipeline, “AON-MG23”, and with the goal of developing a treatment for Parkinson’s disease with “AON-PP23”. Currently, "AON-MG23" has proven its excellent effectiveness in animal transplant models and the drug combination effect has also been confirmed. Currently, it has entered the non-clinical stage and is pursuing research to expand indications by confirming the drug's efficacy in triple-negative breast cancer and lung cancer, with the goal of receiving clinical trial approval from the FDA within 2025.